摘要
目的探讨美沙拉嗪联合培菲康治疗复发型活动期溃疡性结肠炎(UC)的临床疗效。方法90例复发型活动期UC患者随机分为治疗组(48例)和对照组(42例)。对照组采用培菲康治疗,治疗组采用美沙拉嗪联合培菲康治疗,疗程2个月。结果治疗组总有效为91.7%,显著高于对照组(73.8%)(P<0.05)。结论美沙拉嗪联合培菲康治疗复发型活动期UC能有效控制临床症状,临床疗效显著,不良反应少,耐受性好,值得临床推广应用。
Objective To investigate the clinical effects of mesalazine combined with bifico in patients with relapsed active ulcerative colitis （UC）. Methods 90 patients with relapsed active UC were randomly divided into treatment group （48 cases） and control group （42 cases）. The control group＇ s patients were given the treatment by bifico, the treatment group＇ s patients were given the treatment by mesalazine combined with birico, treatment for 2 months. Results The total effective rate of treatment group was 91.7%, significantly higher than that of the control group （73.8%） （P 〈 0.05）. Conclusion The clinical effects of mesalazine combined with bifico to treat the patients with relapsed active UC was significant, adverse reactions less and worthy of clinical application.
出处
《中国现代药物应用》
2009年第21期19-21,共3页
Chinese Journal of Modern Drug Application
